With various chatters related to the ups and downs or SRX, I...

With various chatters related to the ups and downs or SRX, I thought a quick graphic may be useful.

Over the past 18 months, the SP and the mean Analyst target price. In May 2014 the SP and the target was a tad over $16. It's been an interesting year, in 2015 and not for the faint hearted at times.

In 18 months time, we should have the remaining large trial results, and OS for mCRC, and a lot more news on the R&D area. There is risk involved, as the data may disappoint - it often happens in clinical trials. I'd expect some increased volatility over the next 3/6 months.

I'm moderately confident of another 100% increase over the next 18 months, as I believe we are still at the very early stages of SRX becoming a very successful company. Please DYOR as I'm often wrong, and over enthusiastic much of the time.